Pregabalin as an adjunct to phenobarbital, potassium bromide, or a combination of phenobarbital and potassium bromide for treatment of dogs with suspected idiopathic epilepsy

Journal of the American Veterinary Medical Association

Volumn 235, Issue 12, 2009, Pages 1442-1449

  Dewey, Curtis W ^a   Cerda Gonzalez, Sofia ^a   Levine, Jonathan M ^b   Badgley, Britton L ^a   Ducoté, Julie M ^c   Silver, Gena M ^d   Cooper, Jocelyn J ^b   Packer, Rebecca A ^e   Lavely, James A ^f  

^a Department of Obstetrics Gynecology   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c Animal Neurology and Neurosurgery of Texas   (United States)

^d Massachusetts Veterinary Referral Hospital   (United States)

^e PURDUE UNIVERSITY   (United States)

^f VCA Shoreline Veterinary Referral Emergency Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BROMIDE; DRUG DERIVATIVE; PHENOBARBITAL; POTASSIUM BROMIDE; POTASSIUM DERIVATIVE; PREGABALIN;

ANIMAL; ANIMAL DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DOG; DOG DISEASE; DRUG COMBINATION; EPILEPSY; FEMALE; MALE;

ANIMALS; ANTICONVULSANTS; BROMIDES; DOG DISEASES; DOGS; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; GAMMA-AMINOBUTYRIC ACID; MALE; PHENOBARBITAL; POTASSIUM COMPOUNDS;

ANIMALIA; CANIS FAMILIARIS;

EID: 74549194452     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.235.12.1442     Document Type: Conference Paper

References (30)

1. Thomas WB, Dewey CW. Seizures and narcolepsy. In: Dewey CW, ed. A practical guide to canine and feline neurology. 2nd ed. Ames, Iowa: Wiley-Blackwell, 2008;237-259.
2. Boothe DM. Anticonvulsant therapy in small animals. Vet Clin North Am Small Anim Pract 1998;28:411-447.
3. Podell M, Fenner WR. Bromide therapy in refractory canine idiopathic epilepsy. J VetIntern Med 1993;7:318-327.
4. Berendt M, Gredal H, Ersboll AK, et al. Premature death, risk factors, and life patterns in dogs with epilepsy. J Vet Intern Med 2007;21:754-759.
5. Dewey CW. Anticonvulsant therapy in dogs and cats. Vet Clin North Am Small Anim Pract 2006;36:1107-1127.
6. Bialer M. New antiepileptic drugs that are second generation to existing antiepileptic drugs. Expert Opin InvestigDrugs 2006;15:637-647.
7. Sills GJ. The mechanisms of action of gabapentin and pregaba-lin. CurrOpin Pharmacol 2006;6:108-113.
8. Blommel ML, Blommel AL. Pregabalin: an antiepileptic agent useful for neuropathic pain. AmJ Health Syst Pharm 2007;64:1475-1482.
9. 2-delta) subunit as a target for antiepileptic drug discovery. Epilepsy Res 2007;73:137-150.
10. Vartanian MG, Radulovic LL, Kinsora JJ, et al. Activity profile of pregabalin in rodent models of epilepsy and ataxia. EpilepsyRes 2006;68:189-205.
11. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004;45(suppl 6):13-18.
12. Brodie MJ. Pregabalin as adjunctive therapy for partial seizures. Epilepsia 2004;45(suppl 6):19-27.
13. Ryvlin P. Defining success in clinical trials-profiling pregabalin, the newest AED. Eur J Neurol 2005;12(suppl 4):12-21.
14. Piatt SR, Adams V Garosi LS, et al. Treatment with gabapentin of 11 dogs with refractory idiopathic epilepsy. Vfet Rec 2006;159:881-884.
15. Govendir M, Perkins M, Malik R. Improving seizure control in dogs with refractory epilepsy using gabapentin as an adjunctive agent. Aust Vet J 2005;83:602-608.
16. Salazar V, Dewey CW, Schwark W, et al. Pharmacokinetics of single-dose oral pregabalin administration in normal dogs. Vet Anaesth Analg 2009;36:574-580.
17. Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phase HPLC. Ther Drug Monit 2005;27:451-456.
18. Trepanier LA, Van Schoick A, Schwark WS, et al. Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). J Am Vet Med Assoc 1998;213:1449-1453.
19. Farid NA. Fluorescamine use in high-performance liquid chromatographic determination of aminocaproic acid in serum. J Pharm Sci 1979;68:249-252.
20. Dewey CW, Guiliano R, Boothe DM, et al. Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 2004;40:285-291.
21. Von Klopmann T, Rambeck B, Tipold A. Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. JSmall AnimPract 2007;48:134-138.
22. Volk HA, Matiasek LA, Feliu Pascual AL, et al. The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. Vet J 2008;176:310-319.
23. Munana KR. The placebo effect in epilepsy studies, in Proceedings. 26th Am Coll Vet Intern Med Forum 2008;338-340.
24. Chang Y, Mellor DJ, Anderson TJ. Idiopathic epilepsy in dogs: owners' perspectives on management with phenobarbitone and/or potassium bromide. J Small Anim Pract 2006;47:574-581.
25. Radulovic LL, Turck D, Van Hodenberg A, et aL Disposition of gabapentin (Neurontin) in mice, rats, dogs, and monkeys. Drug Metab Dispos 1995;23:441-448.
26. VollmerKO, Von Hodenberg A, KolleEU. Pharmacokinetics and metab olism of gabapentin in rat, dog and man. Drug Res 198636:830-839.
27. Gaskill CL, Cribb AE Pancreatitis associated with potassium bromide/phenobarbital combination therapy in epileptic dogs. Can Vfet J 2000;41:555-558.
28. Steiner JM, Xenoulis PG, Anderson JA,etaL Serum pancreatic lipase immunoreactivity concentrations in dogs treated with potassium bromide and/or phenobarbitaL vet Ther 2008;9:37-44.
29. Elger CE, Brodie MJ, Anhut H, et al. Pregabalin add-on treatment in patients with partial seizures: a novel evaluation of flexible-dose and fixed-dose treatment in a double-blind, placebo-controlled study Epilepsia 2005;46:1926-1936.
30. Beydoun A, Uthman BM, Kugler AR, et al. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy Neurology 2005;64:475-480.